DA2

NG,NG-DIMETHYL-L-ARGININE

DA2 is found in 10 entries.

DA2 in polymers: 6 entries. Examples include 2B2U 2LTO 2V86

DA2 as free ligands, exist in 4 entries. Examples include 4A4G 4A4H 4M5A

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name NG,NG-DIMETHYL-L-ARGININE
Identifiers (2S)-2-amino-5-[(N,N-dimethylcarbamimidoyl)amino]pentanoic acid
Formula C8 H18 N4 O2
Molecular Weight 202.254  g/mol
Type L-PEPTIDE LINKING
Isomeric SMILES CN(C)C(=N)NCCC[C@H](N)C(O)=O
InChI InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1
InChIKey YDGMGEXADBMOMJ-LURJTMIESA-N

Chemical Details

Formal Charge 0
Atom Count 32
Chiral Atom Count 1
Chiral Atoms CA
Bond Count 31
Aromatic Bond Count 0
Leaving Atoms n/a

Drug Info: DrugBank

DrugBank ID DB01686   (Stereoisomeric match)
Name N,N-dimethylarginine
Groups experimental
Description Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. [Wikipedia]
Synonyms
  • Asymmetric dimethylarginine
  • Dimethyl-l-arginine
  • Guanidino-n,n-dimethylarginine
  • N(5)-((Dimethylamino)iminomethyl)-L-ornithine
  • N(5)-[(dimethylamino)(imino)methyl]-L-ornithine
Affected Organism Humans and other mammals
Pharmacology Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is formed by methylation of arginine residues in proteins and released after proteolysis. In this reaction, S-adenosylmethionine is methyldonor and S-adenosylhomocysteine the demethylated product. ADMA and homocysteine are thus biochemically linked. Both plasma homocysteine and ADMA concentrations are increased in patients with renal dysfunction, probably as a result of an impairment in their metabolic, but not urinary, clearance. Hyperhomocysteinemia has been associated with an increased risk of cardiovascular disease in end-stage renal disease, especially in patients without malnutrition and inflammation. Also, plasma ADMA levels have been associated with cardiovascular disease in renal failure patients. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial, nitric oxide-dependent function resulting in decreased vasodilatation, increased smooth muscle cell proliferation, platelet dysfunction and increased monocyte adhesion.
Categories Enzyme Inhibitors
CAS number 102783-24-4
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682